Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors have entered the therapeutic landscape for this indication. The regulatory approvals of targeted therapies, such as Roche / Genentech’s Avastin, AstraZeneca’s Lynparza, Clovis Oncology’s Rubraca, and Tesaro’s Zejula, have changed physicians’ prescribing habits and created new dynamics in treatment sequencing. In December 2018, Lynparza became the first PARP inhibitor to gain FDA approval as a first-line maintenance therapy for ovarian cancer with BRCA mutations.
- What is the uptake of Avastin and Lynparza as maintenance therapies for first-line advanced-stage ovarian cancer according to surveyed oncologists?
- What is the patient share of key therapies for advanced-stage (first- to fourth-line) ovarian cancer?
- What are the key drivers and obstacles determining current prescribing of Avastin and PARP inhibitors for advanced-stage ovarian cancer?
- How do drug-treatment rates vary across key ovarian cancer patient populations, according to stage of disease and line of therapy?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 medical oncologists in the United States fielded in March 2019.
Key drugs covered: Avastin, Lynparza, Zejula, Rubraca